HRP20181002T1 - Injekcija 5 alfa-androstan (alkil)-3 beta, 5, 6 beta-triola i postupak pripreme - Google Patents
Injekcija 5 alfa-androstan (alkil)-3 beta, 5, 6 beta-triola i postupak pripreme Download PDFInfo
- Publication number
- HRP20181002T1 HRP20181002T1 HRP20181002TT HRP20181002T HRP20181002T1 HR P20181002 T1 HRP20181002 T1 HR P20181002T1 HR P20181002T T HRP20181002T T HR P20181002TT HR P20181002 T HRP20181002 T HR P20181002T HR P20181002 T1 HRP20181002 T1 HR P20181002T1
- Authority
- HR
- Croatia
- Prior art keywords
- injection
- androstane
- filtration
- triol
- parts
- Prior art date
Links
- 238000002347 injection Methods 0.000 title claims 17
- 239000007924 injection Substances 0.000 title claims 17
- QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 238000001914 filtration Methods 0.000 claims 5
- 238000004108 freeze drying Methods 0.000 claims 5
- IFRIPYPBJCUNAG-OTMXHXQLSA-N (3s,5r,6r,8s,9s,10r,13s,14s)-10,13-dimethyl-1,2,3,4,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,5,6-triol Chemical compound C([C@]1(O)[C@H](O)C2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 IFRIPYPBJCUNAG-OTMXHXQLSA-N 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 238000004042 decolorization Methods 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 238000011082 depyrogenation Methods 0.000 claims 3
- 239000000945 filler Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000000706 filtrate Substances 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000000845 maltitol Substances 0.000 claims 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 2
- 235000010449 maltitol Nutrition 0.000 claims 2
- 229940035436 maltitol Drugs 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 235000010356 sorbitol Nutrition 0.000 claims 2
- 230000001954 sterilising effect Effects 0.000 claims 2
- 238000004659 sterilization and disinfection Methods 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 239000000811 xylitol Substances 0.000 claims 2
- 235000010447 xylitol Nutrition 0.000 claims 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 2
- 229960002675 xylitol Drugs 0.000 claims 2
- 239000003708 ampul Substances 0.000 claims 1
- 230000003750 conditioning effect Effects 0.000 claims 1
- 229960004756 ethanol Drugs 0.000 claims 1
- 238000011049 filling Methods 0.000 claims 1
- 229960005150 glycerol Drugs 0.000 claims 1
- 229940102223 injectable solution Drugs 0.000 claims 1
- 239000012155 injection solvent Substances 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 claims 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 239000008215 water for injection Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Claims (10)
1. Injekcija 5α-androstan-3β,5,6β-triola, uključujući tekućinsku injekciju s otapalom ili krutu injekciju, sadrži barem jedan topljivi ekscipijens, pri čemu barem jedan topljivi ekscipijens uključuje hidroksipropil-β-ciklodekstrin.
2. Injekcija prema patentnom zahtjevu 1, gdje je 5α-androstan-3β,5,6β-triol prisutan u udjelu masenog omjera 1~20: 40~500 u odnosu na hidroksipropil-β-ciklodekstrin.
3. Injekcija prema patentnom zahtjevu 1 ili 2, gdje topljivi ekscipijens nadalje sadrži izotonično sredstvo za prilagodbu i/ili punilo za ledeno sušenje.
4. Injekcija prema patentnom zahtjevu 3, gdje je izotonično sredstvo za prilagodbu izabrano iz skupine koja se sastoji od natrij klorida, glukoze, manitola, laktoze, ksilitola, sorbitola, maltitola i njihovih smjesa.
5. Injekcija prema patentnom zahtjevu 3, gdje je punilo za ledeno sušenje izabrano iz skupine koja se sastoji od natrij klorida, glukoze, manitola, laktoze, ksilitola, sorbitola, maltitola i njihovih smjesa.
6. Injekcija prema patentnom zahtjevu 1 ili 2, gdje je otapalo tekućinske injekcije izabrano iz skupine koja se sastoji od propandiola, etanola, polietilen glikola 400, polietilen glikola 200, glicerola, vode i njihovih smjesa.
7. Injekcija prema patentnom zahtjevu 3, gdje se injekcija sastoji od (po masi): 1~20 dijelova 5α-androstan-3β,5,6β-triola, 40~500 dijelova hidroksipropil-β-ciklodekstrina, 1~100 dijelova izotoničnog sredstva za prilagodbu, 0~200 dijelova punila za ledeno sušenje, te 0~2000 dijelova otapala.
8. Postupak pripreme injekcije prema patentnom zahtjevu 1, koji sadrži korake
(a) otapanje hidroksipropil-β-ciklodekstrina, 5α-androstan-3β,5,6β-triola i dodatnih topljivih ekscipijensa u vodi za injekciju sekvencijalno kako bi se dobila sirova injekcijska otopina, te
(b1) podlaganje sirove injekcijske otopine dekolorizaciji, depirogenaciji, filtraciji i sterilizaciji kako bi se dobila injekcija, ili
(b2) podlaganje sirove injekcijske otopine dekolorizaciji, depirogenaciji, filtraciji te punjenje filtrata dobivenog filtracijom u ampulu, nakon čega slijedi ledeno sušenje kako bi se dobio prah ledenog sušenja, ili
(b3) podlaganje sirove injekcijske otopine dekolorizaciji, depirogenaciji, filtraciji te sušenje sprejem filtrata dobivenog filtracijom, nakon čega slijedi pakiranje.
9. Postupak prema patentnom zahtjevu 8, gdje se dekolorizacija postiže upotrebom aktiviranog ugljena u količini od 0.05~0.3 wt% injekcije.
10. Postupak prema patentnom zahtjevu 8 ili 9, gdje se sterilizacija provodi pri 115 °C 30 minuta ili pri 121 °C 15 minuta.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010292234XA CN101961311B (zh) | 2010-09-21 | 2010-09-21 | 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法 |
EP11826361.5A EP2620153B1 (en) | 2010-09-21 | 2011-07-08 | 5 alpha-androstane (alkyl)-3 beta,5,6 beta-triol injection and preparation method therefor |
PCT/CN2011/076968 WO2012037834A1 (zh) | 2010-09-21 | 2011-07-08 | 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20181002T1 true HRP20181002T1 (hr) | 2018-08-24 |
Family
ID=43514490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20181002TT HRP20181002T1 (hr) | 2010-09-21 | 2018-06-28 | Injekcija 5 alfa-androstan (alkil)-3 beta, 5, 6 beta-triola i postupak pripreme |
Country Status (22)
Country | Link |
---|---|
US (2) | US9161985B2 (hr) |
EP (1) | EP2620153B1 (hr) |
JP (1) | JP5750680B2 (hr) |
KR (1) | KR101468153B1 (hr) |
CN (1) | CN101961311B (hr) |
AU (1) | AU2011304917B2 (hr) |
BR (1) | BR112013005763B1 (hr) |
CA (1) | CA2809646C (hr) |
CY (1) | CY1120724T1 (hr) |
DK (1) | DK2620153T3 (hr) |
ES (1) | ES2677069T3 (hr) |
HR (1) | HRP20181002T1 (hr) |
HU (1) | HUE038230T2 (hr) |
LT (1) | LT2620153T (hr) |
PL (1) | PL2620153T3 (hr) |
PT (1) | PT2620153T (hr) |
RS (1) | RS57409B1 (hr) |
RU (1) | RU2532354C1 (hr) |
SG (2) | SG188393A1 (hr) |
SI (1) | SI2620153T1 (hr) |
TR (1) | TR201809354T4 (hr) |
WO (1) | WO2012037834A1 (hr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101884638B (zh) | 2010-07-09 | 2011-11-09 | 中山大学 | 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用 |
CN103626818B (zh) | 2012-03-08 | 2016-03-30 | 广州市赛普特医药科技有限公司 | 雄甾-3β,5α,6β-三醇的晶型化合物及其制备方法 |
CN103330946B (zh) * | 2013-05-29 | 2015-03-25 | 广州市赛普特医药科技有限公司 | 5α-雄甾-3β,5,6β-三醇注射剂其制备方法 |
CN104288110B (zh) * | 2013-06-26 | 2017-05-10 | 广州市赛普特医药科技股份有限公司 | 5α‑雄甾‑3β,5,6β‑三醇注射剂及其制备方法 |
WO2015047999A1 (en) * | 2013-09-26 | 2015-04-02 | Polyone Corporation | Sustainable poly(vinyl halide) mixtures for thin-film applications |
CN113350359B (zh) * | 2017-12-29 | 2022-08-16 | 广州市赛普特医药科技股份有限公司 | 5α-雄甾-3β,5,6β-三醇在制备治疗出血性脑卒中药物中的应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2191576A (en) * | 1936-11-21 | 1940-02-27 | Soc Of Chemical Ind | 3,5,6-trihydroxy androstane and pregnane compounds |
IE62095B1 (en) * | 1988-03-29 | 1994-12-14 | Univ Florida | Pharmaceutical formulations for parenteral use |
FR2668945B1 (fr) * | 1990-11-12 | 1993-02-19 | Theramex | Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus. |
US5563131A (en) * | 1994-08-04 | 1996-10-08 | Pherin Corporation | Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods |
WO1997017992A1 (en) * | 1995-11-13 | 1997-05-22 | Supergen, Inc. | Improved formulation for administration of steroid compounds |
US5824668A (en) * | 1996-11-07 | 1998-10-20 | Supergen, Inc. | Formulation for administration of steroid compounds |
US20030060425A1 (en) * | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
CN1232539C (zh) * | 2002-05-10 | 2005-12-21 | 刘云清 | 有机药物与倍他环糊精衍生物的配合物及其制备方法 |
WO2004070048A1 (en) * | 2003-02-07 | 2004-08-19 | Pharmacia & Upjohn Company Llc | A microbial process to prepare 5-androsten-3beta, 7alpha, 15alpha-triol-17-one and related analogues |
CN1706501A (zh) * | 2005-05-27 | 2005-12-14 | 沈阳药科大学 | 亲脂性药物环糊精包合物的制备方法 |
CN101884638B (zh) * | 2010-07-09 | 2011-11-09 | 中山大学 | 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用 |
-
2010
- 2010-09-21 CN CN201010292234XA patent/CN101961311B/zh active Active
-
2011
- 2011-07-08 BR BR112013005763-7A patent/BR112013005763B1/pt active IP Right Grant
- 2011-07-08 SG SG2013016126A patent/SG188393A1/en unknown
- 2011-07-08 RU RU2013105216/15A patent/RU2532354C1/ru active
- 2011-07-08 KR KR1020137006176A patent/KR101468153B1/ko active IP Right Grant
- 2011-07-08 JP JP2013527453A patent/JP5750680B2/ja active Active
- 2011-07-08 WO PCT/CN2011/076968 patent/WO2012037834A1/zh active Application Filing
- 2011-07-08 SI SI201131508T patent/SI2620153T1/en unknown
- 2011-07-08 HU HUE11826361A patent/HUE038230T2/hu unknown
- 2011-07-08 CA CA2809646A patent/CA2809646C/en active Active
- 2011-07-08 LT LTEP11826361.5T patent/LT2620153T/lt unknown
- 2011-07-08 TR TR2018/09354T patent/TR201809354T4/tr unknown
- 2011-07-08 RS RS20180765A patent/RS57409B1/sr unknown
- 2011-07-08 EP EP11826361.5A patent/EP2620153B1/en active Active
- 2011-07-08 SG SG10201400723UA patent/SG10201400723UA/en unknown
- 2011-07-08 PL PL11826361T patent/PL2620153T3/pl unknown
- 2011-07-08 AU AU2011304917A patent/AU2011304917B2/en active Active
- 2011-07-08 PT PT118263615T patent/PT2620153T/pt unknown
- 2011-07-08 US US13/821,849 patent/US9161985B2/en active Active
- 2011-07-08 ES ES11826361.5T patent/ES2677069T3/es active Active
- 2011-07-08 DK DK11826361.5T patent/DK2620153T3/en active
-
2015
- 2015-08-28 US US14/839,869 patent/US9265837B1/en active Active
-
2018
- 2018-06-28 HR HRP20181002TT patent/HRP20181002T1/hr unknown
- 2018-06-29 CY CY181100681T patent/CY1120724T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181002T1 (hr) | Injekcija 5 alfa-androstan (alkil)-3 beta, 5, 6 beta-triola i postupak pripreme | |
HRP20200567T1 (hr) | Stabilni injektabilni farmaceutski pripravci koji sadrže 2-hidroksipropil-beta-ciklodekstrin i alfaksalon | |
JP2008526991A5 (hr) | ||
JP2016518442A5 (hr) | ||
BR112014020930A2 (pt) | método para produzir uma formulação seca de um agente biofármaco, e, formulação de um agente biofármaco | |
HRP20160802T1 (hr) | Čvrsti farmaceutski pripravci koji sadrže derivate biopterina i upotreba takvih pripravaka | |
CN103224539B (zh) | 一种天麻素化合物及其药物组合物 | |
EA201400802A1 (ru) | Способ приготовления курительной композиции без табака для кальяна | |
CN103159769A (zh) | 一种多索茶碱化合物及其药物组合物 | |
CN105078905A (zh) | 一种注射用盐酸多西环素冻干粉针剂的制备方法 | |
RU2018128913A (ru) | Инъекционная фармацевтическая композиция, включающая трабектедин, для применения вне желудочно-кишечного тракта и способ её получения | |
CN103520121A (zh) | 注射用维库溴铵冻干粉针剂及其制备方法 | |
WO2016116882A2 (en) | Novel compositions of carfilzomib | |
HRP20140676T1 (hr) | Formulacije deoksikolne kiseline i njezinih soli | |
BR112012010400A2 (pt) | composição co-processada, processo para preparar uma composição útil como um excipiente farmacêutico, formulação de granulado ou comprimido, método, e, forma de dosagem sólida | |
CN103446064B (zh) | 一种绿原酸粉针剂及其制备方法 | |
RU2017125264A (ru) | Состав для инъекций на основе силибина и способ его получения | |
CN104820026A (zh) | 一种荔枝核滴丸质量检测方法 | |
RU2015138710A (ru) | Жевательная композиция для перорального приема и способ ее получения | |
JP2016507535A5 (hr) | ||
CN106342929A (zh) | 花卉杀虫剂及其制备方法 | |
CN102727507A (zh) | 天麻派立辛提取物冻干粉针剂及其制备方法 | |
CN103565754B (zh) | 注射用亚叶酸钙组合物的冻干粉剂的制备方法 | |
CN103142514B (zh) | 一种含胸腺法新的注射用冻干组合物及其制备方法 | |
RU2535049C1 (ru) | Способ получения стабилизированной субстанции дротаверина гидрохлорида |